Home/Filings/4/0001209191-23-010544
4//SEC Filing

Martin Daniel C. 4

Accession 0001209191-23-010544

CIK 0001654151other

Filed

Feb 16, 7:00 PM ET

Accepted

Feb 17, 4:12 PM ET

Size

9.1 KB

Accession

0001209191-23-010544

Insider Transaction Report

Form 4
Period: 2023-02-15
Martin Daniel C.
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2023-02-15+11,15159,540 total
  • Sale

    Common Stock

    2023-02-16$15.10/sh1,159$17,50058,381 total
  • Award

    Stock Option (Right to Buy)

    2023-02-15+44,60044,600 total
    Exercise: $15.48Exp: 2033-02-14Common Stock (44,600 underlying)
Footnotes (3)
  • [F1]The reporting person was awarded 11,151 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026.
  • [F2]This sale was to cover tax liabilities in the vesting of restricted stock.
  • [F3]This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023.

Issuer

Deciphera Pharmaceuticals, Inc.

CIK 0001654151

Entity typeother

Related Parties

1
  • filerCIK 0001752827

Filing Metadata

Form type
4
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 4:12 PM ET
Size
9.1 KB